Thursday, 6 November 2014

ScHARRNews - Thursday 6th November 2014



NICE on sipuleucel-T (Provenge)
£244,000 per QALY for a sub-group, £61,400 for a further sub-group and doesn’t meet end-of-life guidance.That’s the tweet over with.  Here’s a bit more detail from NICE:The Committee noted that, for the sub-group of patients who had not had prior chemotherapy and using a discounted price for abiraterone, the cost per QALY (quality-adjusted life year) was at least £512,000 (company’s analyses) or a
Researching the Provision of Psychosocial Interventions for Older People Diagnosed with Mild-Moderate Dementia
The focus of our research is on the current and planned provision of psychosocial interventions for older people living in the community who are diagnosed with early to moderate dementia. Older people living with this serious condition both need and deserve services once diagnosed, but service provision varies considerably across the region and country. Therefore in the first instance we are condu

No comments:

Post a Comment